Bailard Inc. Has $2.11 Million Holdings in Celgene Co. (CELG)

Share on StockTwits

Bailard Inc. lowered its position in shares of Celgene Co. (NASDAQ:CELG) by 11.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 32,944 shares of the biopharmaceutical company’s stock after selling 4,378 shares during the period. Bailard Inc.’s holdings in Celgene were worth $2,111,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Jennison Associates LLC grew its stake in shares of Celgene by 50.2% during the 3rd quarter. Jennison Associates LLC now owns 8,228,124 shares of the biopharmaceutical company’s stock worth $736,335,000 after purchasing an additional 2,748,302 shares during the period. FMR LLC grew its stake in shares of Celgene by 26.0% during the 3rd quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock worth $919,890,000 after purchasing an additional 2,119,257 shares during the period. Edgewood Management LLC grew its stake in shares of Celgene by 13.2% during the 3rd quarter. Edgewood Management LLC now owns 15,757,525 shares of the biopharmaceutical company’s stock worth $1,410,141,000 after purchasing an additional 1,832,981 shares during the period. Janus Henderson Group PLC grew its stake in shares of Celgene by 15.3% during the 3rd quarter. Janus Henderson Group PLC now owns 10,461,658 shares of the biopharmaceutical company’s stock worth $936,215,000 after purchasing an additional 1,391,617 shares during the period. Finally, AQR Capital Management LLC grew its stake in shares of Celgene by 38.8% during the 3rd quarter. AQR Capital Management LLC now owns 4,090,345 shares of the biopharmaceutical company’s stock worth $366,044,000 after purchasing an additional 1,143,027 shares during the period. Institutional investors own 75.15% of the company’s stock.

In related news, Director James J. Loughlin sold 23,466 shares of the stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $87.29, for a total value of $2,048,347.14. Following the sale, the director now directly owns 62,102 shares of the company’s stock, valued at approximately $5,420,883.58. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.39% of the stock is currently owned by corporate insiders.

A number of equities analysts have recently weighed in on CELG shares. BidaskClub cut shares of Celgene from a “hold” rating to a “sell” rating in a research note on Wednesday, October 24th. Leerink Swann cut shares of Celgene from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 3rd. Mizuho set a $117.00 price target on shares of Celgene and gave the stock a “buy” rating in a research note on Tuesday, October 30th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a research note on Thursday, October 25th. Finally, Robert W. Baird raised shares of Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 price target on the stock in a research note on Friday, January 4th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $109.29.

Shares of NASDAQ CELG opened at $89.74 on Thursday. The stock has a market capitalization of $62.45 billion, a P/E ratio of 11.79, a price-to-earnings-growth ratio of 0.41 and a beta of 1.72. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $97.43. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 31st. The biopharmaceutical company reported $2.39 EPS for the quarter, beating the Zacks’ consensus estimate of $2.32 by $0.07. The firm had revenue of $4.04 billion for the quarter, compared to analysts’ expectations of $3.98 billion. Celgene had a net margin of 26.48% and a return on equity of 125.35%. During the same period in the prior year, the company earned $2.00 EPS. As a group, equities research analysts expect that Celgene Co. will post 10.01 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://weekherald.com/2019/02/14/bailard-inc-has-2-11-million-holdings-in-celgene-co-celg.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply